Fujiwara Keiichi, Monk Bradley, Devouassoux-Shisheboran Mojgan
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka City, Saitama, Japan,
Curr Oncol Rep. 2014 Dec;16(12):416. doi: 10.1007/s11912-014-0416-y.
Adenocarcinoma (AC) of the uterine cervix is the second most frequent tumor type following squamous cell carcinoma (SCC). According to the National Comprehensive Cancer Network (NCCN) guidelines, there is no difference in the treatment strategy between SCC and AC. However, there are a number of studies that suggest a worse prognosis for AC compared to SCC. In this comprehensive review, we will try to find the reason why AC is different from SCC, and then discuss what we need to do to improve the prognosis of AC. Uterine cervical AC is clearly different from SCC based on its molecular pathogenesis, histological appearance, and clinical behavior. Therefore, it will be necessary to make a different treatment strategy, particularly for patients with locally advanced and metastatic or recurrent disease. It is most important to intensify our research into the molecular profile of AC, so that we can develop more appropriate targeted therapies. Because of its rarity, international collaboration among clinical trials with translational components will be key to increasing cure rates and improving survivorship.
子宫颈腺癌（AC）是仅次于鳞状细胞癌（SCC）的第二常见肿瘤类型。根据美国国立综合癌症网络（NCCN）指南，SCC和AC的治疗策略没有差异。然而，有多项研究表明，与SCC相比，AC的预后更差。在这篇综述中，我们将试图找出AC与SCC不同的原因，然后讨论我们需要做些什么来改善AC的预后。子宫颈AC在分子发病机制、组织学表现和临床行为方面明显不同于SCC。因此，有必要制定不同的治疗策略，特别是对于局部晚期、转移性或复发性疾病的患者。加强对AC分子特征的研究最为重要，以便我们能够开发出更合适的靶向治疗方法。由于其罕见性，具有转化成分的临床试验之间的国际合作将是提高治愈率和改善生存率的关键。
